Analgesic effects mediated by neuronal nicotinic acetylcholine receptor agonists: Correlation with desensitization of α4β2* receptors
Autor: | Terry Hauser, Kristen G. Jordan, Yun-De Xiao, Patrick M. Lippiello, Merouane Bencherif, John W. James, Jason Speake, Sharon R. Letchworth, Jiahui Zhang, Mazurov Anatoly A, Phil S. Hammond, Katherine M. Van Dyke |
---|---|
Rok vydání: | 2012 |
Předmět: |
Male
medicine.medical_treatment Analgesic Pain Pharmaceutical Science Motor Activity Receptors Nicotinic Pharmacology Binding Competitive PC12 Cells Cell Line Mice Cell Line Tumor Formaldehyde medicine Animals Humans Nicotinic Agonists Receptor Desensitization (medicine) Analgesics Chemistry HEK 293 cells In vitro Rats Nicotinic acetylcholine receptor HEK293 Cells Nociception Nicotinic agonist |
Zdroj: | European Journal of Pharmaceutical Sciences. 47:813-823 |
ISSN: | 0928-0987 |
DOI: | 10.1016/j.ejps.2012.09.014 |
Popis: | Nicotinic α4β2* agonists are known to be effective in a variety of preclinical pain models, but the underlying mechanisms of analgesic action are not well-understood. In the present study, we characterized activation and desensitization properties for a set of seventeen novel α4β2*-selective agonists that display druggable physical and pharmacokinetic attributes, and correlated the in vitro pharmacology results to efficacies observed in a mouse formalin model of analgesia. ABT-894 and Sazetidine-A, two compounds known to be effective in the formalin assay, were included for comparison. The set of compounds displayed a range of activities at human (α4β2)(2)β2 (HS-α4β2), (α4β2)(2)α5 (α4β2α5) and (α4β2)(2)α4 (LS-α4β2) receptors. We report the novel finding that desensitization of α4β2* receptors may drive part of the antinociceptive outcome. Our molecular modeling approaches revealed that when receptor desensitization rather than activation activitiesat α4β2* receptors are considered, there is a better correlation between analgesia scores and combined in vitro properties. Our results suggest that although all three α4β2 subtypes assessed are involved, it is desensitization of α4β2α5 receptors that plays a more prominent role in the antinociceptive action of nicotinic compounds. For modulation of Phase I responses, correlations are significantly improved from an r(2) value of 0.53 to 0.67 and 0.66 when HS- and LS-α4β2 DC(50) values are considered, respectively. More profoundly, considering the DC(50) at α4β2α5 takes the r(2) from 0.53 to 0.70. For Phase II analgesia scores, adding HS- or LS-α4β2 desensitization potencies did not improve the correlations significantly. Considering the α4β2α5 DC(50) value significantly increased the r(2) from 0.70 to 0.79 for Phase II, and strongly suggested a more prominent role for α4β2α5 nAChRs in the modulation of pain in the formalin assay. The present studies demonstrate that compounds which are more potent at desensitization of α4β2* receptors display better analgesia scores in the formalin test. Consideration of desensitization propertiesat α4β2* receptors, especially at α4β2α5, in multiple linear regression analyses significantly improves correlations with efficacies of analgesia. Thus, α4β2* nicotinic acetylcholine receptor desensitization may contribute to efficacy in the mediation of pain, and represent a mechanism for analgesic effects mediated by nicotinic agonists. |
Databáze: | OpenAIRE |
Externí odkaz: |